Loading…

Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits

Galantamine is a rather weak acetylcholinesterase (AChE) inhibitor, currently approved for the symptomatic treatment of Alzheimer's disease, with possible additional allosteric potentiating effects at the nicotinic ACh receptor (nAChR). Earlier data from in vitro biochemical tests suggest that...

Full description

Saved in:
Bibliographic Details
Published in:Brain research 2005-02, Vol.1033 (2), p.186-193
Main Authors: Geerts, Hugo, Guillaumat, Pierre-Olivier, Grantham, Christopher, Bode, Wilhelmina, Anciaux, Katelijne, Sachak, Sohel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Galantamine is a rather weak acetylcholinesterase (AChE) inhibitor, currently approved for the symptomatic treatment of Alzheimer's disease, with possible additional allosteric potentiating effects at the nicotinic ACh receptor (nAChR). Earlier data from in vitro biochemical tests suggest that donepezil is 40- to 500-fold more potent than galantamine in inhibiting AChE. In this study, both brain levels and K i values for AChE inhibition for donepezil and galantamine in rat, mouse, and rabbit after subcutaneous application were determined. Clearance of galantamine from the brain is in general faster that donepezil and is faster in rabbits compared to rats and mice. The brain-to-plasma ratio for galantamine and donepezil, respectively, ranges from 1.2 to 1.5 in the rabbit, 3.3 to 5.2 in the mouse, and 6.6 to 13 in the rat. Galantamine doses between 1.5 and 5 mg/kg are appropriate to reach brain levels within the documented optimal allosteric potentiating ligand dose-response. K i values of brain AChE inhibition for galantamine and donepezil, respectively, are 7.1 and 2.3 μg/g in rats, 8.3 and 0.65 μg/g for mice, and 19.1 and 1.3 μg/g in rabbits. The data also suggest that for a similar degree of brain AChE inhibition, 3–15 times higher galantamine than donepezil doses are needed.
ISSN:0006-8993
1872-6240
DOI:10.1016/j.brainres.2004.11.042